Biotech | December 17, 2021
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
Effectiveness of Covaxin against the Omicron variant is currently being studied
Effectiveness of Covaxin against the Omicron variant is currently being studied
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
The interim data combines three mRNAs into one therapy injected directly into the tumour
The division is expected to grow to over a 100-member strong team by 2022
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Subscribe To Our Newsletter & Stay Updated
